Rentschler Biopharma agreed to serve as CDMO partner for BioNTech whereby Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase III clinical trial.
Rentschler Biopharma will handle downstream processing to provide purified drug substance. Process and product-related impurities will be removed from the intermediate pool, which has been previously derived from mRNA synthesis.
